Full Press Release Details
Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million
ANTONIO, Texas (February 25, 2024) - bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) announced today it has
entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding warrants to purchase
an aggregate of 2,438,473 of the Company's shares of common stock (the "Existing Warrants"). In consideration for the
immediate exercise in full of the Existing Warrants for gross cash proceeds of approximately $1.4 million, the exercising holders will
receive in a private placement new unregistered warrants (the "New Warrants") to purchase up to an aggregate of 2,926,168
shares of common stock (equal to 120% of the shares of common stock issued in connection with the exercise of the Existing Warrants)
with an exercise price of $0.85 per share. The New Warrants are initially exercisable on the date that stockholder approval of the exercise
of the New Warrants is obtained and will expire five years from the date of such approval. In connection with the exercise of the Existing
Warrants, the Company agreed to reduce the exercise price of the Existing Warrants from $1.50 to $0.58 per share. The exercise of the
Existing Warrants and the issuance of the New Warrants are expected to occur on February 25, 2025.
closing of the offering is expected to occur on or about February 26, 2025, subject to the satisfaction of customary closing conditions.
The gross proceeds from the warrant inducement are expected to be approximately $1.4 million, excluding any proceeds that may be received
upon the exercise of the New Warrants and before deducting placement agent fees and other offering expenses payable by the Company.
Capital is acting as sole placement agent for the for the warrant inducement transaction.
press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities
in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of such jurisdiction.
Lung uses advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate
malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath Lung
incorporates a fluorescent porphyrin, TCPP, that is preferentially taken up by cancer and cancer-related cells. Clinical study results
demonstrated that CyPath Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients
at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage cancer can improve
outcomes and increase patient survival.
bioAffinity Technologies, Inc.
Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer
treatments. The Company's first product, CyPath Lung, is a noninvasive test that has shown high sensitivity,
specificity and accuracy for the detection of early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed
Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com
press release contains forward-looking statements, including statements regarding the anticipated exercise of warrants, the anticipated
gross proceeds from the Company's offering of securities and the expected closing of the offering. Forward-looking statements can
be identified by words such as "believes," "expects," "estimates," "intends," "may,"
"plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are
based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers
of this press release are cautioned not to place undue reliance on any forward-looking statements. Because forward-looking statements
relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and
many of which are outside of the Company's control. Many factors could cause actual future events to differ materially from the
forward-looking statements in this press release, including but not limited to the Company's ability to close the offering and
risks and uncertainties included under the heading "Risk Factors" in the Company's Annual Report on Form 10-K, Quarterly
Reports on Form 10-Q and other reports filed with the SEC from time to time. The Company does not undertake any obligation to update
any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities
(733-2447) or 407-491-4498